Clinical Trial Update: To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD) [EARLY_Phase 1]

View source ↗

Summary

This clinical trial update outlines a Phase 1 intravitreal study of EXG202 for wet age-related macular degeneration, focusing on safety and preliminary efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• EXG202 (EXG202)

Snippet

Sponsor: Guangzhou Jiayin Biotech Ltd | Conditions: Wet Age-related Macular Degeneration (wAMD), Wet Age-related Macular Degeneration | EARLY_Phase 1 | Status: NOT_YET_RECRUITING